Previous 10 | Next 10 |
2020 was an outright disaster for Amarin (NASDAQ: AMRN) . Its stock plunged 77% because the drugmaker lost a key patent lawsuit over its flagship product Vascepa. But 2021 has been much better for Amarin so far. Good news related to the initiation of the regulatory review process ...
Amarin Corp. plc (AMRN) reported Q4 2020 results today that beat analyst expectations on both EPS and revenue.Revenue in the quarter was $167.3M, a 17% increase from the prior-year period, and a record for the company.The record revenue in the quarter was due to strong sales of Vascepa as pre...
Amarin (NASDAQ:AMRN) is scheduled to announce Q4 earnings results on Thursday, February 25th, before market open.The consensus EPS Estimate is -$0.00 vs. $0.04 in 4Q19 and the consensus Revenue Estimate is $164.21M (+14.6% Y/Y).Over the last 2 years, AMRN has beaten EPS estimates 75...
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's fourth quarter and full year 2020 financial results and provide...
Amarin (NASDAQ: AMRN) spiked nearly 8% on Tuesday before falling to earth and landing essentially flat over Monday's close. The day's moves followed a seemingly encouraging development for the only drug the company has on the market. Amarin announced that the regulatory approval...
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that its corporate partner in China, Edding, has progressed VASCEPA ® (icosapent ethyl) into commencement of the regulatory review processes in Mainland Chi...
It's been a long and painful path to market success for Amarin. Legal roadblocks devastated the share price and brought generics to market much sooner than expected. The company has begun to rebound and has a new opportunity in the EU. Let's explore what the stock is worth. ...
Amarin (NASDAQ: AMRN) enjoyed a 7.7% ride skyward on Monday. This was on the back of a regulatory document filed after market hours on Friday detailing some new incentives for top management. Amarin disclosed in the document that it has drafted and implemented an Executive Sever...
Shares of Matinas BioPharma Holdings (NYSEMKT: MTNB) were crashing 32.7% lower as of 3:01 p.m. EST on Monday. The steep decline came after the company announced disappointing results from a phase 2 clinical study of Lypdiso in reducing triglycerides. Matinas had good news and ba...
Amarin ([[AMRN]] +0.3%) has received positive recommendation from the Committee for Medicinal Products for Human Use ((CHMP)) for its marketing application for icosapent ethyl for the reduction of risk of cardiovascular events in patients at high cardiovascular risk, under the brand name...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...